The name of the disease, nature of the disease, condition, expected therapeutic effect, doctor, and future treatment policy are of course explained in detail. Unlike informed consent, the flow of information is not one-way, and the doctor will determine a mutually acceptable treatment policy while grasping the patient's characteristics and freely expressing personal opinions. We want to value the process.
Treatment will be provided after the patient fully understands and consents to the treatment, but when visiting the hospital for the first time, it is recommended that not only the patient himself but also his family come to the hospital as much as possible. Recommended.
As a treatment method, standard treatment is first considered unless there is a special reason. Standard treatment is a treatment method that has been proven in clinical trials and is valid on medical and scientific grounds that ``current treatment is likely to produce the best effect'' ( (Of course, this is subject to change as new treatments emerge.) In addition, we will propose the best treatment for the patient, taking into account the patient's general condition and side effects depending on the treatment method, the patient's wishes and other circumstances.
As a clinical trial, we are also working on investigational treatments such as clinical trials of new drugs and new combination chemotherapy. Patients who wish to participate in clinical trials or clinical trials may be able to anticipate and select new treatment methods, so we will talk to those who wish to do so when explaining treatment.
Emphasizing QOL (quality of life), after the introduction of chemotherapy, treatment will be continued at outpatient clinics at our hospital or at affiliated medical institutions in the region. I try to keep my life going as long as possible.
In addition, at our Outpatient Chemotherapy Center, we collaborate with specialists in each field, cancer specialist nurses, cancer chemotherapy certified nurses, and cancer specialist pharmacists to provide safe and comfortable outpatient chemotherapy. I am trying.
Our department provides advanced team medical care for patients with adult solid cancers, including gastrointestinal cancer.
Medical record
outpatient cancer chemotherapy
Approximately 10,000 outpatient cancer chemotherapy patients are administered and managed annually.
For more information, please refer to the Outpatient Chemotherapy Center sectionsecond opinion
We are always ready to provide a variety of second opinions from Japanese Society of Medical Oncology instructors and Oncology Pharmacotherapist. About 40 cases/year
Clinical trials/clinical trials
We have conducted a large number of clinical studies and trials, including various clinical studies, as well as many international joint clinical studies and development trials (Phase II, Phase III). We have performed it for many cancers such as gastric cancer, colon cancer, pancreatic cancer, biliary tract cancer, and hepatocellular carcinoma.
For details, please refer to the Clinical Trial and Clinical Trial Management Center section.Departmental statistics
Main diseases/treatments
clinical research
Clinical research involving therapeutic intervention includes clinical trials (company-initiated and doctor-initiated) and clinical trials (doctor-initiated, multi-center trial, etc.). Early clinical trials (phase I trials) to confirm the safety of unapproved drugs, phase II trials to evaluate efficacy and safety, and phase III trials to establish standard treatments and apply for drug approval We have a wide range of research implementation systems up to testing.
Clinical Research and InnovationClinical trials (company-initiated and doctor-initiated)
Some of the clinical trials currently underway are shown in the table below.
| Test name/subject name | Target disease | test drug | Explanatory text (PDF) |
| Comparison study of standard treatment of trastuzumab and tucatinib combined with mFOLFOX6 in the first-line treatment of HER2-positive metastatic colorectal cancer |
Metastatic colorectal cancer |
Tucatinib | |
|---|---|---|---|
| A randomized, multicenter, study of zanidatamab in combination with chemotherapy with or without tislelizumab in patients with HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). Phase III study |
HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA |
・Zanidatamab(ZW25) ・Tislelizumab (BGB-A317) |
|
| ONO-4578-08: ONO-4578, nivolumab, and fluoropyrimidines for subjects with HER2-negative, chemotherapy-naive, unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) A multicenter, phase II, randomized, double-blind study comparing the efficacy and safety of a combination therapy of drugs and platinum-based chemotherapy (hereinafter referred to as chemotherapy) with a combination therapy of placebo, nivolumab, and chemotherapy. comparative test |
Advanced or recurrent gastric cancer that cannot be cured or resected |
ONO-4578 | |
| Phase III study of dostarlimab as perioperative treatment in patients with T4N0 or Stage III resectable colon cancer with previously untreated dMMR/MSI-H |
colon cancer |
dostarlimab | |
| Phase I study of ONO-7913 Open-label first-line therapy with ONO-7913, ONO-4538 and standard of care FOLFOX plus bevacizumab or cetuximab in patients with unresectable advanced or recurrent colorectal cancer Uncontrolled study |
Unresectable advanced or recurrent colorectal cancer |
ONO-7913, ONO-4538 (Nivolumab) | |
| Phase Ib/III comparing Bemarituzumab plus chemotherapy and nivolumab to chemotherapy and nivolumab in patients with FGFR2b-overexpressing advanced gastric and esophagogastric junction cancer test |
stomach cancer |
Bemarituzumab | |
| A study comparing bemarituzumab plus chemotherapy with placebo plus chemotherapy in patients with previously untreated FGFR2b-overexpressing advanced gastric or esophagogastric junction cancer |
stomach cancer |
Bemarituzumab | |
| Phase 3 clinical trial of trastuzumab deruxtecan as second-line treatment for patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma | stomach cancer | DS-8201a |
Clinical trials (doctor-initiated: multi-center trials, etc.)
| Test name/subject name | responsible doctor | approval date | Explanatory text (PDF) |
| Searching for common clinical and molecular biological factors in treatment-resistant cervical cancer: A multicenter retrospective observational study | Hisaaki Yasui | August 2024 | |
|---|---|---|---|
| Real-world data analysis of pemigatinib therapy for unresectable or recurrent biliary tract cancer with FGFR2 fusion gene or FGFR2 gene rearrangement | Hisaaki Yasui | May 2024 | |
| Multicenter collaborative study on collecting real-world data (RWD) in cancer treatment | Hisaaki Yasui | June 2021 | |
| Multicenter joint research on comprehensive collection and utilization of in-hospital real-world data (RWD) related to cancer treatment (CONNECT-2) | Hisaaki Yasui | February 2024 | |
| Observational study of BRAF mutation-positive unresectable colorectal cancer in clinical practice | Hisaaki Yasui | February 2024 | |
| A multicenter retrospective observational study of cases that underwent an expert panel at Kyoto University Hospital. | Hisaaki Yasui | December 2023 | |
| Multi-center joint research on biomarker development using AI multi-omics for patients with advanced solid malignancies (SCRUM-Japan MONSTAR-SCREEN-2) | Hisaaki Yasui | June 2021 | |
| A retrospective observational study to explore the usefulness of anamorelin for gastrointestinal cancer associated with cachexia | Hisaaki Yasui | May 2023 | |
| A randomized phase III controlled trial comparing CAPOX therapy with surgery alone as adjuvant chemotherapy for high-risk stage II and low-risk stage III colon cancer with negative circulating tumor DNA and curative resection (VEGA trial) | Hisaaki Yasui | May 2020 | |
| Registry study for colorectal cancer that can be radically treated (GALAXY trial) | Hisaaki Yasui | April 2020 | |
| Observational study evaluating the utility of germline mutation identification in patients with solid tumors and their relatives (BRANCH study) | Hisaaki Yasui | October 2022 | |
| Observational study on efficacy and safety of nivolumab + chemotherapy in treatment-naïve advanced or recurrent gastric cancer in real-world settings | Hisaaki Yasui | October 2022 | |
| Multicenter study of profiling and monitoring of cancer-associated genetic alterations in circulating tumor DNA and gut microbiota in unresectable solid malignant tumors (SCRUM-Japan MONSTAR-SCREEN) | Hisaaki Yasui | October 2019 | |
| Research on liquid biopsy for patients with gastrointestinal and abdominal malignancies including colorectal cancer; GI-screen accompanying research GOZILAstudy | Hisaaki Yasui | October 2018 |
In addition, we are conducting a number of multi-center investigator-doctor clinical trials.
Each clinical study has patient conditions (eligibility criteria, exclusion criteria). In addition, the recruitment status of patients changes from time to time. If you have any inquiries, please contact us at the following.
contact address
神戸市立医療センター中央市民病院 腫瘍内科部長 安井 久晃
神戸市中央区港島南町２丁目1-1
TEL 078-302-4321(大代表)
news
On June 1, 2019, cancer gene panel testing (OncoGuide NCC Oncopanel, FoundationOne CDx) (hereinafter referred to as this test) for some cancer patients was covered by insurance. There are many issues with its operation, and we have kept you waiting for a long time at our hospital. For more information, please refer to the "Cancer Genome Testing Outpatient" section.
In addition, cancer gene panel testing by free medical care is also being carried out as before.
Oncology
Department of General Oncology, Advanced Medical Center Hospital and Kobe City Medical Center General Hospital For patients who have undergone Oncology and have agreed to participate in the following clinical studies
In the 12 studies currently underway in our department, the research director has changed due to the transfer of the doctor. Due to the enactment of the Clinical Research Act, the research implementation system has also been partially changed.
Details of the research can be found at the information disclosure destination.
Clinical Research Implementation Plan/Research Outline Public System (jRCT) UMIN clinical trial registration system[Target clinical research]
All patient recruitment at our hospital has been completed.
| exam name | Information disclosure destination |
|---|---|
| Randomized controlled phase II/III study of carboplatin + etoposide combination therapy (CE therapy) and carboplatin + irinotecan combination therapy (CI therapy) for elderly extensive-stage small cell lung cancer (JCOG1201) | jRCTs031180193 |
| Randomized controlled trial of irinotecan + cisplatin therapy and etoposide + cisplatin therapy in patients with completely resected high-grade neuroendocrine lung cancer (JCOG1206) | jRCTs031180216 |
| Randomized controlled trial of gefitinib monotherapy versus gefitinib plus cisplatin + pemetrexed for EGFR mutation-positive advanced non-squamous non-small cell lung cancer (JCOG1404) | UMIN000020242 |
| Randomized controlled phase III trial of docetaxel versus nab-paclitaxel for previously treated advanced or recurrent non-small cell lung cancer (J-AXEL) | jRCTs071180037 |
| A phase II study to investigate the significance of therapeutic effect based on primary site estimation using next-generation sequencing for untreated cancer of unknown primary (NGSCUP) | UMIN000016794 |
| An Open-Label, Randomized, Controlled Phase III Clinical Trial Comparing First-Line Bevacizumab + Erlotinib Versus Erlotinib Monotherapy for Patients with EGFR Mutant Non-Small Cell Lung Cancer (NEJ026) | jRCTs031180056 |
| Phase II clinical trial of afatinib for treatment-naïve advanced non-squamous non-small cell lung cancer aged 75 years or older with EGFR mutation (NEJ027) | jRCTs031180136 |
| A randomized phase 2 study on the efficacy of zoledronic acid administered every 4 weeks and every 8 weeks in lung cancer with bone metastases (Hanshin Cancer Research Group Study 0312) | jRCTs061180054 |
| A phase II study to investigate the efficacy and safety of immune priming effect against irradiated field lesions by Nivolumab combined with palliative radiotherapy for advanced-stage non-small cell lung cancer (Hanshin cancer 0116/PRINCIPAL study) | jRCTs051180174 |
| A multicenter, single-arm phase II trial of afatinib plus bevacizumab combination therapy in patients with advanced EGFR-mutant non-small cell lung cancer after failure of osimertinib | jRCTs051180205 |
| A Phase II Study of Carboplatin + Paclitaxel for Advanced Squamous Cell Lung Cancer Complicated with Idiopathic Interstitial Pneumonia (IP 001 (Sq)) | jRCTs051180149 |
| Phase II study of carboplatin + paclitaxel + bevacizumab for advanced non-small cell lung cancer excluding squamous cell lung cancer with idiopathic interstitial pneumonia (IP 002 (non-Sq)) | jRCTs061180046 |
Contact information
If you have any questions regarding the relevant clinical research, please contact us at the contact information below.
【問い合わせ先】
神戸市立医療センター中央市民病院 腫瘍内科 部長
安井 久晃 （ やすい ひさてる ）
〒650-0047 神戸市中央区港島南町2丁目1-1
電話番号：078-302-4321（代表）
| Mon | Tue | Wed | Thu | Fri | |
| 7:30〜 8:15 |
lung cancer conference |
||||
|---|---|---|---|---|---|
| 8:15〜 8:30 |
Oncology conference |
breast cancer conference |
gynecological tumor conference |
||
| 8:30〜 8:50 |
|||||
| 8:50〜 9:30 |
outpatient chemotherapy conference |
outpatient chemotherapy conference |
outpatient chemotherapy conference |
outpatient chemotherapy conference |
outpatient chemotherapy conference |
| 16:00〜 17:00 |
Oncology rounds | ||||
| 17:30〜 18:00 |
1st: Chemotherapy Committee | ||||
| 18:00〜 19:00 |
digestive disorders joint conference |
1st: Cancer Board |
Oncology is one of the core clinical departments of our cancer center and serves as a point of contact for cancer patients. In addition to patients who require chemotherapy, medical Oncology triages patients who have difficulty in making a definitive diagnosis or the best treatment method has not yet been determined, and provides joint care with related clinical departments. I will.
Regarding cancer chemotherapy, we treat adult solid cancer patients, including gastrointestinal cancer. Furthermore, according to the patient's wishes, chemotherapy is also possible through medical cooperation with our hospital and referral/regional medical institutions.
In addition, we can also support clinical trials and clinical trials of new anticancer drugs, so if there are patients who are interested, we would appreciate it if you could contact us.
"Clinical Oncology Practice" vol.1.10 No.3 (2014)
Our hospital was published in a magazine.
From November 1, 2017, the Advanced Medical Center Hospital will be integrated with Kobe City Medical Center and operated as the South Building. As a result, the Department of General Oncology at the Advanced Medical Center Hospital will continue to provide medical care as one of the Kobe City Medical CenterOncology groups. Oncology beds are allocated not only in the main building but also in the south building, and the inpatient ward is determined depending on the patient's condition and the purpose of treatment.
Inpatients are kindly requested to understand that they may change wards during their hospitalization (not only the Main Building but also the Main Building ⇔ South Building).
